EGFR and non-small cell lung carcinoma: In a subgroup analysis of a phase II trial (N = 49), the presence of an EGFR mutation or anaplastic lymphoma kinase rearrangement was predictive of a reduced risk of death in patients with sOMD NSCLC treated with first-line TKI (n = 8), but no subgroup analyses with the effect of the addition of LRT were performed because of the small population.5